JLE

Journal de Pharmacie Clinique

MENU

An interactive tool to monitor the appropriate use of innovative or expensive drugs in oncology: experience of the periodic drug survey developed by the FNCLCC Volume 26, issue 3, Septembre 2007

Figures

See all figures

Authors
Centre Léon Bérard, 28 rue Laënnec, 69008 Lyon, Partenariat et communication, FNCLCC, 101 rue de Tolbiac, 75654 Paris cedex 13, Bureau d’études cliniques et thérapeutiques, FNCLCC, 101 rue de Tolbiac, 75654 Paris Cedex 13, Société Cemka-Eval, 73, boulevard Joffre, 92340 Bourg La Reine

The definition of the appropriateness of drug usage in oncology raises specific questions considering the fast rate of emerging therapeutic innovation, the severity of the conditions, the associated costs and the time taken in marketing authorization procedures. The French health authorities have recently regulated this domain in the context of a reform of hospital funding based on DRGs which included new modalities for reimbursement of costly drugs and devices. The French Federation of Comprehensive Cancer Centers (FNCLCC) took the initiative in 2004 to develop an original approach to promote an interactive regulation process in this domain. The objectives were to enhance among pharmacists and clinicians awareness about EBM and costs of prescription and provide tools allowing a benchmarking of practices among the 20 French Oncology Centers. The principles and first results of this approach are presented and discussed.